| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.3 | 0.6 |
| Gross profit | 1.0 | 0.6 |
| Net income | -6.0 | -3.6 |
| EPS (diluted, $ a share) | $-3.76 | $-4.76 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +112.6% |
|---|---|
| Gross margin | 81.3% |
| Operating margin | -456.2% |
10-Q filed with the SEC, NASDAQ: SCNX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Scienture Holdings, Inc.: key numbers
- Share price
- $2.99Close, Nov 16
- Market cap
- $5.35M
- Shares outstanding
- 1.79MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Scienture Holdings, Inc.
All →Scienture Holdings Shareholder Meeting
Scienture Holdings held its 2026 Annual Meeting of Stockholders on October 28, 2026, where shareholders voted on four key proposals. Stockholders elected five directors to the board, ratified CM3 Advisory as the independent auditor for fiscal year 2026, and approved executive compensation on a non-binding advisory basis.
Scienture Holdings Business Update
Scienture Holdings announced preliminary Q3 2026 revenue of approximately $1.22 million, a 256% sequential increase driven by the launch of REZENOPY and growth in Arbli sales. The company also reported regaining compliance with Nasdaq's minimum bid price requirement after its stock closed above $1.00 for ten consecutive trading days.
Scienture Holdings Reverse Stock Split
Scienture Holdings, Inc. implemented a 1-for-25 reverse stock split of its common stock effective October 5, 2026. The action is intended to increase the per-share price to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split reduces the outstanding share count from approximately 41.1 million to approximately 1.6 million shares.
Scienture Holdings Investor Presentation
Scienture Holdings, Inc. has posted a revised investor presentation to its corporate website and filed it as an exhibit to this 8-K. The company intends to use the presentation in upcoming meetings with analysts and potential investors to discuss its projects, financial performance, and growth opportunities.